| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/02/2023 | 22.88% | Argus Research | → $110 | Initiates Coverage On | → Buy |
| 03/28/2023 | -65.37% | BTIG | $20 → $31 | Maintains | Buy |
| 12/12/2022 | 61.97% | TD Cowen | $130 → $145 | Maintains | Outperform |
| 06/28/2022 | — | UBS | Downgrades | Neutral → Sell | |
| 06/07/2022 | — | JP Morgan | Upgrades | Neutral → Overweight | |
| 05/31/2022 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 03/16/2022 | — | Deutsche Bank | Upgrades | Hold → Buy | |
| 01/25/2022 | — | Liberum | Downgrades | Hold → Sell | |
| 12/20/2021 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 01/15/2021 | — | Deutsche Bank | Initiates Coverage On | → Buy | |
| 01/17/2020 | 391.51% | B of A Securities | $420 → $440 | Reiterates | → Neutral |
| 01/03/2020 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 11/18/2019 | — | UBS | Downgrades | Buy → Neutral | |
| 11/18/2019 | — | Barclays | Upgrades | Equal-Weight → Overweight | |
| 09/17/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 09/13/2019 | 346.83% | B of A Securities | $355 → $400 | Reiterates | → Neutral |
| 08/30/2019 | — | Jefferies | Downgrades | Hold → Underperform | |
| 06/20/2019 | — | Deutsche Bank | Downgrades | Buy → Hold | |
| 06/11/2019 | — | Barclays | Upgrades | Underweight → Equal-Weight | |
| 04/29/2019 | — | Credit Suisse | Upgrades | Neutral → Outperform | |
| 01/29/2019 | — | Exane BNP Paribas | Initiates Coverage On | → Outperform | |
| 12/14/2018 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 12/11/2018 | 218.36% | Jefferies | → $285 | Assumes | → Hold |
| 11/19/2018 | — | JP Morgan | Upgrades | Neutral → Overweight | |
| 10/08/2018 | — | B of A Securities | Downgrades | Buy → Neutral |
What is the target price for Novo Nordisk (NVO)?
The latest price target for Novo Nordisk (NYSE: NVO) was reported by Argus Research on October 2, 2023. The analyst firm set a price target for $110.00 expecting NVO to rise to within 12 months (a possible 22.88% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Novo Nordisk (NVO)?
The latest analyst rating for Novo Nordisk (NYSE: NVO) was provided by Argus Research, and Novo Nordisk initiated their buy rating.
When is the next analyst rating going to be posted or updated for Novo Nordisk (NVO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novo Nordisk, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novo Nordisk was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
Is the Analyst Rating Novo Nordisk (NVO) correct?
While ratings are subjective and will change, the latest Novo Nordisk (NVO) rating was a initiated with a price target of $0.00 to $110.00. The current price Novo Nordisk (NVO) is trading at is $89.52, which is within the analyst's predicted range.